| 翻訳と辞書 |
| Mapp Biopharmaceutical ： ウィキペディア英語版 |
Mapp Biopharmaceutical
Mapp Biopharmaceutical is an American pharmaceutical company based in San Diego, California. It is responsible for the research and development of ZMapp, a drug which is still under development, comprising three humanized monoclonal antibodies as a treatment for Ebola virus disease.〔(【引用サイトリンク】title=ZMapp Information Sheet )〕〔"(Mystery Ebola virus serum manufactured by San Diego firm )". Los Angeles Times. August 4, 2014.〕 The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak. The ZMapp drug is a result of the collaboration between Mapp Biopharmaceutical, LeafBio (the commercial arm of Mapp Biopharmaceutical),〔(【引用サイトリンク】title=LeafBio )〕 Defyrus Inc. (Toronto), the U.S. government and the Public Health Agency of Canada.〔 The antibody work came out of research projects funded by Defense Advanced Research Projects Agency(DARPA) more than a decade ago, and years of funding by the Public Health Agency of Canada.〔Helen Branswell for The Canadian Press. Aug. 5, 2014 (Experimental Ebola drug based on research discoveries from Canada's national lab )〕 ZMapp is manufactured in the tobacco plant ''Nicotiana benthamiana'' in the bioproduction process known as "pharming" by Kentucky BioProcessing, a subsidiary of Reynolds American.
==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Mapp Biopharmaceutical」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|